Document is current
Any future updates will be listed below
-
Authors
Jung, Young-ho
Ku, Young Ah
Moon, Jayoon
Kim, Seunghoon
Ryu, Jin Suk
Yoon, Chang Ho
Chung, Myung Hee
Kim, Yong Ho
Kim, Mee Kum
Kim, Dong Hyun http://orcid.org/0000-0002-3985-990X
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (No. RS-2023-00243720)
a grant of Korea University Anam Hospital (K2319651 and K2225511)
- License Information
-
More Information
Article History
Received: 14 December 2023
Accepted: 9 May 2024
First Online: 1 June 2024
Declarations
:
: The protocol was approved by the Institutional Animal Care and Use Committee of Seoul National University Biomedical Research Institute (IACUC No. 20–0178-S1A0).
: Not applicable.
: None of the authors have a proprietary interest in the methods described in this article. Dong Hyun Kim developed a patent for the topical use of RCI001 as treatment of various ocular diseases. (Republic of Korea: 10–1816277/ US: 10/675294) Yong Ho Kim is CEO of RudaCure Co., Ltd.
